克柔念珠菌分离株的抗真菌药敏谱：CLSI 和 Etest 方法学之间的相关性。
Antifungal susceptibility profile of Trichosporon isolates: correlation between CLSI and etest methodologies.
机构信息
Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais , Belo Horizonte, MG , Brasil.
出版信息
Braz J Microbiol. 2010 Apr;41(2):310-5. doi: 10.1590/S1517-83822010000200008. Epub 2010 Jun 1.
Abstract
The aim of the present study was to evaluate the antifungal susceptibility profile of Trichosporon species isolated from different sources employing the Clinical and Laboratory Standards Institute (CLSI) method and E-test method. Thirty-four isolates of Trichosporon spp. and six CBS reference samples were tested for their susceptibility to Amphotericin B, 5-flucytosine, Fluconazole, Itraconazole, Voriconazole and Terbinafine. All species showed high Minimun Inhibitory Concentrations (MIC) for Itraconazole and susceptibility to Fluconazole, The comparison among the results obtained by the CLSI method and E-test revealed larger discrepancies among 5-flucytosine and Itraconazole. The present work provides epidemiological data that could influence therapeutic choices. Furthermore, the comparison between different methodologies could help to analyze results obtained by different laboratories.
摘要
本研究旨在评估采用临床和实验室标准研究所（CLSI）方法和 E 试验方法从不同来源分离的 Trichosporon 种的抗真菌药敏谱。对 34 株 Trichosporon spp. 和 6 株 CBS 参考菌株进行了两性霉素 B、5-氟胞嘧啶、氟康唑、伊曲康唑、伏立康唑和特比萘芬的药敏试验。所有种均对伊曲康唑表现出高最小抑菌浓度（MIC）和对氟康唑的敏感性，CLSI 方法和 E 试验结果之间的比较显示 5-氟胞嘧啶和伊曲康唑之间存在更大的差异。本研究提供了可能影响治疗选择的流行病学数据。此外，不同方法之间的比较有助于分析不同实验室获得的结果。
相似文献
1
Antifungal susceptibility profile of Trichosporon isolates: correlation between CLSI and etest methodologies.
Braz J Microbiol. 2010 Apr;41(2):310-5. doi: 10.1590/S1517-83822010000200008. Epub 2010 Jun 1.
2
MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method.
J Antimicrob Chemother. 2020 May 1;75(5):1194-1205. doi: 10.1093/jac/dkz568.
3
Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
J Antimicrob Chemother. 1998 Sep;42(3):321-31. doi: 10.1093/jac/42.3.321.
4
Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates.
Diagn Microbiol Infect Dis. 2002 Jun;43(2):107-11. doi: 10.1016/s0732-8893(02)00376-0.
5
6
The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Virulence. 2015;6(5):476-86. doi: 10.1080/21505594.2015.1020273. Epub 2015 Mar 9.
7
Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
Antimicrob Agents Chemother. 2013 Oct;57(10):4841-7. doi: 10.1128/AAC.00850-13. Epub 2013 Jul 22.
8
[Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].
Mikrobiyol Bul. 2018 Jan;52(1):35-48. doi: 10.5578/mb.63991.
9
Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods.
J Clin Microbiol. 2010 Jan;48(1):154-61. doi: 10.1128/JCM.01096-09. Epub 2009 Nov 4.
10
Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates.
J Clin Microbiol. 1996 Jul;34(7):1691-3. doi: 10.1128/JCM.34.7.1691-1693.1996.
引用本文的文献
1
Optimized conditions for broth microdilution susceptibility testing of Trichosporon spp. to clinical antifungals.
Braz J Microbiol. 2025 Aug 22. doi: 10.1007/s42770-025-01766-y.
2
Case report: Diagnostic and therapeutic challenges of fungal endocarditis by in a child with congenital heart defects.
Front Pediatr. 2023 Oct 6;11:1200215. doi: 10.3389/fped.2023.1200215. eCollection 2023.
3
A Comprehensive Review of Trichosporon spp.: An Invasive and Emerging Fungus.
Cureus. 2021 Aug 21;13(8):e17345. doi: 10.7759/cureus.17345. eCollection 2021 Aug.
4
Epidemiological profile and antifungal susceptibility pattern of species in a tertiary care hospital in Chandigarh, India.
Curr Med Mycol. 2021 Mar;7(1):19-24. doi: 10.18502/cmm.7.1.6179.
5
Uncommon Non- Yeasts in Healthy Turkeys-Antimicrobial Susceptibility and Biochemical Characteristic of Trichosporon Isolates.
Pathogens. 2021 Apr 30;10(5):538. doi: 10.3390/pathogens10050538.
6
Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen.
Front Microbiol. 2016 Oct 17;7:1629. doi: 10.3389/fmicb.2016.01629. eCollection 2016.
7
Onycholysis and Chromonychia: A Case Caused by Trichosporon inkin.
Skin Appendage Disord. 2016 Feb;1(3):144-6. doi: 10.1159/000441065. Epub 2015 Nov 24.
8
Emerging pan-resistance in Trichosporon species: a case report.
BMC Infect Dis. 2016 Apr 14;16:148. doi: 10.1186/s12879-016-1477-3.
9
Subcutaneous Infection Associated with Trichosporon ovoides: A Case Report and Review of Literature.
Mycopathologia. 2016 Apr;181(3-4):285-90. doi: 10.1007/s11046-015-9958-2. Epub 2015 Oct 22.
10
Emerging Trichosporon asahii in elderly patients: epidemiological and molecular analysis by the DiversiLab system.
Eur J Clin Microbiol Infect Dis. 2014 Sep;33(9):1497-503. doi: 10.1007/s10096-014-2099-6. Epub 2014 Apr 10.
本文引用的文献
1
Genetic diversity and antifungal susceptibility testing of Trichosporon asahii isolated of Intensive Care Units patients.
Braz J Microbiol. 2008 Jul;39(3):585-92. doi: 10.1590/S1517-838220080003000033. Epub 2008 Sep 1.
2
Invasive Trichosporon cutaneum infection in an infant with wilms' tumor.
Braz J Microbiol. 2008 Jan;39(1):59-60. doi: 10.1590/S1517-838220080001000014. Epub 2008 Mar 1.
3
Urinary tract infection by Trichosporon asahii.
Indian J Med Microbiol. 2006 Oct;24(4):294-6. doi: 10.4103/0255-0857.29392.
4
[Nosocomial infection due to Trichosporon asahii: clinical revision of 22 cases].
Rev Iberoam Micol. 2006 Jun;23(2):85-9. doi: 10.1016/s1130-1406(06)70019-5.
5
Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis.
Antimicrob Agents Chemother. 2006 Jun;50(6):2240-3. doi: 10.1128/AAC.00045-06.
6
Microbiological characteristics of medically important Trichosporon species.
Mycopathologia. 2005 Oct;160(3):217-25. doi: 10.1007/s11046-005-0112-4.
7
Susceptibility patterns and molecular identification of Trichosporon species.
Antimicrob Agents Chemother. 2005 Oct;49(10):4026-34. doi: 10.1128/AAC.49.10.4026-4034.2005.
8
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.
J Clin Microbiol. 2003 Jan;41(1):78-83. doi: 10.1128/JCM.41.1.78-83.2003.
9
Nosocomial fungemia due to Trichosporon asteroides: firstly described bloodstream infection.
Diagn Microbiol Infect Dis. 2002 Jun;43(2):167-70. doi: 10.1016/s0732-8893(02)00385-1.
10
Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates.
Diagn Microbiol Infect Dis. 2002 Jun;43(2):107-11. doi: 10.1016/s0732-8893(02)00376-0.
Zotero 插件